Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Minority Interest (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Minority Interest readings, the most recent being $79000.0 for Q1 2026.

  • On a quarterly basis, Minority Interest fell 20.2% to $79000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $79000.0, a 20.2% decrease, with the full-year FY2025 number at $84000.0, down 20.75% from a year prior.
  • Minority Interest hit $79000.0 in Q1 2026 for Barinthus Biotherapeutics, down from $84000.0 in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $400000.0 in Q1 2022 to a low of $79000.0 in Q1 2026.
  • Median Minority Interest over the past 5 years was $183000.0 (2024), compared with a mean of $200764.7.
  • Biggest five-year swings in Minority Interest: tumbled 98.81% in 2022 and later decreased 18.54% in 2024.
  • Barinthus Biotherapeutics' Minority Interest stood at $305000.0 in 2022, then crashed by 30.82% to $211000.0 in 2023, then plummeted by 49.76% to $106000.0 in 2024, then decreased by 20.75% to $84000.0 in 2025, then decreased by 5.95% to $79000.0 in 2026.
  • The last three reported values for Minority Interest were $79000.0 (Q1 2026), $84000.0 (Q4 2025), and $96000.0 (Q3 2025) per Business Quant data.